In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration
By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in…
New York State EtE Campaign Update: Successes & Challenges
By Jeremiah Johnson The December 2017 release of the New York State (NYS) 2016 HIV/AIDS surveillance data shows that the efforts to End the Epidemic (EtE) in New York are having an impact. In 2014, Governor Andrew Cuomo backed a…
Slide Decks for Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy
Introduction For many HIV-positive people—particularly those who initiate treatment soon after infection—combination antiretroviral therapy (ART) is associated with robust improvements in CD4+ T cell counts, enhanced immune function, and a life expectancy comparable to that of similar HIV-negative individuals. But a…
It’s Time to Deliver – Including Pregnant and Lactating Women in Clinical Research
Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant…